Walleye Capital’s Amicus Therapeutics FOLD Stock Holding History

Walleye Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$1.42K	–	4589
2025 Q4	$1.42K	Sell	100 -6,100	-98%	-$59.9K	﹤0.01%	4382
2025 Q3	$48.9K	Sell	6,200 -48,800	-89%	-$347K	﹤0.01%	4005
2025 Q2	$315K	Buy	+55,000	New	+$355K	﹤0.01%	3013
2025 Q1	–	Sell	-18,000	Closed	-$170K	–	4522
2024 Q4	$170K	Sell	18,000 -40,600	-69%	-$422K	﹤0.01%	3865
2024 Q3	$626K	Buy	58,600 +51,800	+762%	+$564K	﹤0.01%	3091
2024 Q2	$67.5K	Sell	6,800 -9,200	-58%	-$94.4K	﹤0.01%	4852
2024 Q1	$188K	Buy	+16,000	New	+$205K	﹤0.01%	4017
2023 Q4	–	Sell	-5,600	Closed	-$68.1K	–	5132
2023 Q3	$68.1K	Buy	+5,600	New	+$72.2K	﹤0.01%	4101
2019 Q3	–	Sell	-8,000	Closed	-$100K	–	2012
2019 Q2	$100K	Sell	8,000 -1,800	-18%	-$22.8K	0.01%	1224
2019 Q1	$133K	Buy	+9,800	New	+$120K	0.02%	925

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Walleye Capital's FOLD Position: Q2 2026 in Review

Walleye Capital sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 15,399 shares — an estimated $223K sold.

Walleye Capital first reported a position in FOLD in Q1 2019 and held it in 12 quarters. The position peaked at $4.32M in Q3 2024. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Walleye Capital reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 15,399 Amicus Therapeutics shares in Q2 2026, an estimated $223K.
Walleye Capital first reported a position in Amicus Therapeutics in Q1 2019 and held it in 12 quarters.
Walleye Capital's Amicus Therapeutics position peaked at $4.32M in Q3 2024.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.